AstraZeneca announced that it has come to an agreement to acquire Aescap Life Sciences portfolio company Fusion Pharmaceuticals for $ 21 and a CVR (Contingent value right) of $ 3 per share.

Aescap portfolio company 4DMT saw its share price increase by 85% yesterday after it announced positive results from its clinical trial for a gene therapy treatment of a form of macular degeneration (Wet AMD).

The biotech sector has been going through some heavy turmoil since the start of the Covid-19 epidemic. Nonetheless, with the sector being back on track but still being seriously undervalued compared to other sectors, it is a promising sector for investors again. Read why!

Today, the FDA approved the world’s first ‘gene-editing’ therapy, Casgevy. This treatment for sickle cell disease (SCD) is based on the 2020 Nobel Prize-winning CRISPR/Cas9 technology and is developed by Aescap portfolio companies Crispr and Vertex

Aescap portfolio company Ionis announced today that its medicine candidate Olezarsen has shown a statistically significant reduction in triglyceride levels in a phase 3 clinical study.

Aescap portfolio company Rocket Pharmaceuticals yesterday went up 39% after it came to an agreement with the FDA that it only needs to enroll 12 patients in a pivotal clinical trial with their gene therapy for a fatal heart disease.

Promising undervalued biotech companies offer an excellent opportunity for significant future returns. Waiting until the sector is back in the spotlight often results in a missed opportunity. As share prices will have risen by then.

Today Argenx, an Aescap Life Sciences company, has announced positive results for its final clinical trial in patients diagnosed with CIDP (chronic inflammatory demyelinating polyneuropathy).

Several of the Aescap portfolio companies in both the Aescap Life Sciences and Aescap Genetics fund have an internal team with hundreds of AI experts. Is this just a hype or is there a real added value? And what are they aiming for?

UCB is a biopharma company with over 8 600 employees, headquartered in Brussels, Belgium The company develops and manufactures multiple medicines, sold in 40 countries. In this company showcase we describe why we think UCB is an interesting biopharmaceutical growth story, even after 95 years of existence.